Released Nov 11, 2021, after the close
10-Q filed Nov 12, 2021, 43 days after period end · 0001390478-21-000036
Q3 2021 · 10-Q
Revenue$0.00$0.00 — vs Q3 2020−100.0% vs Q2 2021
Net Income-$7.09M-$7.09M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.45-$0.45 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$6,977,000N/M
Operating Cash Flowderived-$5,878,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$7.09M | -$4.47M | -$4.20M | -$290.00K |
| EPS Diluted | -$0.45 | -$0.53 | -$2.68 | -$26.75 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR